GLP-1

Bank of America spends over $250 million annually on GLP-1 weight loss drugs for employees, combining access with health coaching to reduce long-term healthcare costs. Microsoft reported $24.1 billion in AI revenue from OpenAI, which constitutes 70% of its AI business, despite diversification efforts. Vital Signals raised $15 million to launch a $399 cuffless blood pressure wearable, Signal Ring, entering a competitive market with unproven real-world reliability.

Tim McGraw and Faith Hill’s 29-year-old daughter claims Ozempic, a GLP-1 medication, caused her eating disorder to return. She disclosed using the drug to address symptoms of polyendocrine metabolic ovarian syndrome (PMOS).

'Temporal wasting' is a newly reported side effect of GLP-1 weight loss drugs that causes patients to appear prematurely aged, raising concerns among medical professionals.

The rise of GLP-1 weight loss drugs has led to uncomfortable body-related conversations in workplaces, as exemplified by Isabel Haneder's experience in Germany. These discussions intersect with health insurance costs and legal ambiguities, creating tensions between employees and employers.

Americans are increasingly going direct with GLP-1 prescriptions for weight loss, positioning retail pharmacy chains like Walmart, Costco, and Amazon as major beneficiaries.

Ally Shapiro, daughter of Jill Zarin, revealed she underwent breast augmentation after losing 50 pounds via GLP-1 weight loss, which caused a reduction in breast volume described as looking like 'pancakes.'

Patients taking GLP-1 medications like Ozempic, Wegovy, or Zepbound may need extended fasting or adjusted care before surgery due to slowed stomach emptying, which increases aspiration risk under anesthesia. Physician anesthesiologists require detailed medication information to ensure safe procedures, though most patients undergo surgery without complications.

The author, Rachel Varina, discusses how starting Wegovy, a GLP-1 medication, transformed her travel habits by reducing food cravings and altering her approach to dining. She now prioritizes experiences over meals, packs snacks to manage appetite, and emphasizes hydration due to side effects like nausea and diarrhea.

Kendra Wilkinson shared a dramatic weight-loss update after taking GLP-1. The former Playboy model stated she now fits into her old jeans.

Kendra Wilkinson shared a dramatic weight-loss update after using GLP-1. She mentioned fitting into her old jeans as a result of the treatment.

FedEx is expanding into healthcare logistics by focusing on business-to-business healthcare shipping, part of its strategy to prioritize four B2B verticals. The company aims to capitalize on the growing GLP-1 market in healthcare.

Galderma, a Botox maker, is experiencing an early boost from the 'Ozempic face' trend linked to increased GLP-1 use. The company's CEO expects rising demand for treatments addressing facial volume loss associated with this trend.

Brittany Cartwright disclosed a 20lb weight loss and credited body-shamers for motivating her to use GLP-1. She highlighted the role of online criticism in prompting her decision to adopt the treatment.

Novo Nordisk sued Eli Lilly over claims that its weight-loss medications work better than Novo's, alleging deceptive advertising with outdated trials. The lawsuit, filed in New Jersey, accuses Lilly of comparing high doses of Zepbound to lower doses of Wegovy and Ozempic. Novo seeks a court order to stop the ads and a correction campaign, with a potential preliminary injunction if compliance is not voluntary.

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading GLP-1 advertisements. The lawsuit seeks to halt these ads and mandate corrective advertising.

America's use of GLP-1 medications, such as Ozempic, has nearly quadrupled in two years, contributing to a national trend of weight loss through injection-based treatments.

A woman was hospitalized after allegedly overdosing on GLP-1 medications, while a doctor highlighted subtle signs of excessive use. The incident underscores concerns about potential risks associated with GLP-1 drug administration.

Two letters discuss healthcare challenges: one describes a man's suicide linked to delayed COPD medication approval, and another addresses insurance barriers for weight loss drugs. A third letter mentions pregnancy centers, though details are incomplete.

Biogen's experimental Alzheimer's drug diranersen showed slowed cognitive decline in a mid-stage trial, prompting a potential Phase 3 trial. A study highlighted potential frailty risks in older adults using Eli Lilly's Zepbound and Novo Nordisk's Wegovy, urging closer monitoring for seniors.

Mwyngil Therapeutics, a new biotech startup, is developing obesity treatments without targeting the GLP-1 receptor, which most competitors use. CEO Luba Greenwood, a biotech veteran, emphasized the company's focus on non-GLP-1 approaches to avoid 'me too' drug development in the weight loss market.

A woman developed a 'large, mucus-covered mass' in her stomach after taking GLP-1, leading to severe abdominal pain, nausea, and vomiting. She discovered a 'goopy green' mass and found relief by consuming diet cola.

A study suggests that a 'longevity diet' may naturally increase GLP-1, a hormone linked to reduced hunger and blood sugar management, while also decreasing body fat. Certain foods are highlighted for enhancing GLP-1's effects, contrasting with drug-based approaches.

Doctors have observed a trend where significant weight loss from GLP-1 use causes feet to appear bonier, looser, or deflated. The phenomenon is being referred to as 'Ozempic feet' among medical professionals.

Doctors have observed a trend where significant weight loss from GLP-1 medications leads to visible changes in feet, such as appearing bonier, looser, or deflated. This side effect, referred to as 'Ozempic feet,' is being highlighted as a concern among users of these drugs.

Vivani Medical is developing an implant containing semaglutide, the active ingredient in Novo Nordisk's obesity treatment Wegovy and diabetes drug Ozempic, as a new approach to help patients maintain weight loss.

The article highlights a personalized GLP-1 plan as the key to accessible weight loss, emphasizing its ease of use. It suggests that this approach simplifies the weight loss process.

Yale University researchers easily obtained GLP-1 prescriptions online using fake patient profiles, with some prescriptions issued in under five minutes and minimal clinician interaction. A study published in JAMA medical journal details how researchers tested 49 websites to secure these prescriptions.

Medicare has initiated a GLP-1 pilot program. The article highlights that Medicare coverage of these weight loss drugs could benefit millions of people.

A Harvard University working paper found that women taking GLP-1 weight loss medications were 27 percentage points more likely to find a job if they were unemployed before treatment. The study also linked the drugs to improved dating prospects for women.

Medicare is now covering some GLP-1 weight loss drugs at a cost of $50, making these previously expensive treatments more affordable for many older Americans.

The article discusses Medicare's GLP-1 Bridge program, which provides coverage for GLP-1 receptor agonists to manage diabetes and obesity. It aims to address gaps in access to these medications for eligible beneficiaries.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.

Peptides are widely promoted in health and beauty for benefits like weight loss and tissue repair, but many sold as 'research only' lack FDA approval. The FDA is easing access to peptides despite warnings about undermining drug approval, while experts note that only rigorously studied, FDA-approved peptides (like Tirzepatide and Semaglutide) have strong scientific backing.

Jenny Mollen reported severe side effects, including 'blood everywhere,' from microdosing Tirzepatide, a GLP-1 weight loss drug, while taking a cocktail of peptides.

A man was granted compassionate-use access to an experimental GLP-1 drug developed by Eli Lilly. The exclusive report details the sole individual given special access to the obesity treatment, as covered in STAT's health policy newsletter.

UPS is investing $48 million to build 27 temperature-controlled facilities across three continents to meet the rising demand for refrigerated pharmaceuticals driven by the GLP-1 drug boom. The expansion reflects growing logistical challenges for shipping refrigerated medications.

The new GLP-1 generation includes daily tablets and 'blockbuster fat jabs' for obesity treatment set to arrive in the UK, with claims of being more affordable than Mounjaro.

Glanbia, a protein-powder maker, is experiencing a share price increase driven by the GLP-1 craze. The company's stock is rallying as the trend gains popularity.

Accidental GLP-1 medication overdoses have increased significantly, with a nearly 1,500% rise in poison control calls since 2019. Errors often stem from measurement confusion, compounded medications, and inadequate patient education rather than intentional misuse, according to experts like Dr. Ivania Rizo and Dr. Leslie Golden.